Ga-68 DOTATATE PET/CT for Neuroendocrine Tumors

Ga-68 DOTATATE PET/CT images neuroendocrine tumors by binding somatostatin receptors, and its physics — a 68-minute half-life, energetic positrons, and on-site generator production — sets the acquisition protocol, the SUV quantification chain, and the Krenning-score reporting that make the result clinically defensible. A trustworthy SSTR PET program controls three linked layers: the radiopharmaceutical (radiochemical and radionuclidic purity), the scanner (performance and SUV calibration), and the interpretation (physiologic biodistribution and standardized Krenning scoring), because the diagnostic scan is also the gate for Lu-177 DOTATATE therapy.¹²

Somatostatin-receptor (SSTR) PET has become the reference functional imaging test for well-differentiated neuroendocrine tumors (NETs). Head-to-head and meta-analytic evidence shows Ga-68 DOTATATE PET/CT detects more lesions, more often changes management, and carries a lower radiation burden than the older In-111 pentetreotide (OctreoScan) scan it replaced.²³⁴ But that clinical value rests on physics and quality control, and Ga-68 imposes a specific set of constraints a qualified medical physicist must understand and document.

Introduction

Neuroendocrine tumors arise from cells of the diffuse neuroendocrine system, most commonly in the gastroenteropancreatic tract and lungs. Well-differentiated NETs characteristically overexpress somatostatin receptors, especially subtype 2 (SSTR2), on their cell surface. A somatostatin analogue labeled with a positron emitter binds this target, so PET/CT can map receptor-expressing disease throughout the body. The most widely used agent is Ga-68 DOTATATE (gallium Ga-68 DOTA-Tyr3-octreotate), available in the United States through the FDA-approved cold kit NETSPOT; the closely related agents Ga-68 DOTATOC and Ga-68 DOTANOC share the same DOTA-chelated somatostatin-analogue design.¹⁵

Ga-68 DOTATATE PET/CT is used to detect and localize primary and metastatic NETs, to stage and restage disease, and — critically — to select and monitor patients for somatostatin-receptor-targeted radionuclide therapy.¹²⁶ This guide takes the physics and quantitative-imaging angle: why Ga-68 behaves the way it does, how the agent is produced and tested, how the acquisition protocol and SUV chain are held together, how the Krenning score standardizes interpretation, how DOTATATE compares with In-111 pentetreotide and FDG, and how the scan pairs with Lu-177 DOTATATE in the theranostic pathway.

This is a different tracer and a different indication from our companion article on Ga-68 PSMA PET/CT: PSMA targets prostate-specific membrane antigen in prostate cancer, whereas DOTATATE targets somatostatin receptors in NETs. The two share Ga-68 physics and much of the QC scaffolding but diverge in biology, reporting, and their therapeutic partners. DRPS supports nuclear medicine and PET/CT programs with PET/CT and nuclear medicine physics and accreditation support.

Topic Explanation

What is Ga-68 DOTATATE PET/CT?

Ga-68 DOTATATE PET/CT is a molecular imaging exam in which a gallium-68-labeled somatostatin analogue is injected, allowed to bind SSTR-expressing tissue, and imaged on a PET/CT scanner that records the paired 511 keV annihilation photons. The CT provides attenuation correction and anatomic localization; the PET provides the functional map of somatostatin-receptor density, commonly quantified by standardized uptake value (SUV) and graded visually by the Krenning score.

Several terms recur throughout this guide:

• DOTATATE — DOTA-Tyr3-octreotate, an octreotide-derived somatostatin analogue with high affinity for SSTR2, chelated to Ga-68 through the DOTA macrocycle. It is a receptor agonist, which promotes internalization and accumulation of the tracer.¹
• SSTR2 — somatostatin receptor subtype 2, the dominant target overexpressed by well-differentiated NETs.
• Krenning score — a 0-to-4 visual scale grading tumor uptake against normal liver and spleen reference tissue.¹⁷
• Theranostics — the diagnostic-plus-therapeutic strategy in which the same targeting vector carries an imaging radionuclide (Ga-68) or a therapeutic one (Lu-177).

Why the radionuclide and the vector both matter

An SSTR PET agent has two independently important halves. The targeting vector (the DOTA-conjugated peptide) determines what the tracer binds and how avidly; DOTATATE, DOTATOC, and DOTANOC differ modestly in receptor-subtype affinity but are clinically comparable for routine NET imaging.¹ The radionuclide (Ga-68) sets the half-life that drives logistics and decay correction, the positron branching and energy that drive image counts and intrinsic resolution, and the production route that drives availability and on-site quality control. Because the same DOTA vector can instead carry a therapeutic radionuclide such as Lu-177, the choice of label is what converts a diagnostic scan into a therapy — the essence of the theranostic pair. For the radionuclide landscape behind this, see our overview of common PET and radiopharmaceutical-therapy isotopes.

Key Technical Principles

Ga-68 decay physics

Ga-68 decays predominantly by positron emission — about 89% positron branching, with the balance by electron capture — and has a physical half-life of roughly 68 minutes (measured values cluster near 67.7-67.9 minutes). Its positrons are relatively energetic, with a maximum energy near 1.9 MeV (about 1.899 MeV) and a correspondingly higher mean energy than F-18, so they travel farther in tissue before annihilating.⁸ Those numbers set three practical realities: a short half-life that makes decay correction unforgiving, a high positron yield that gives good count statistics per decay, and a longer positron range that imposes a small intrinsic-resolution penalty relative to F-18 agents — the same physics we detail for Ga-68 PSMA imaging.

Because Ga-68 decays so quickly, timing errors translate directly into activity errors. Activity at time $t$ follows the exponential decay law:

where $A_0$ is the activity at the reference time and $\lambda$ is the decay constant fixed by the half-life $T_{1/2}$:

A single half-life removes half the activity in just over an hour. Across the typical 40-to-90-minute uptake interval between calibration, injection, and acquisition, the decay correction is large, so the injection time must be recorded accurately and applied consistently between the dose calibrator and the scanner. An error of a few minutes in the recorded injection time biases the decay-corrected activity — and therefore the SUV — by a few percent.

Positron range and intrinsic resolution

The longer positron range of Ga-68 is the main reason it cannot quite match the best intrinsic resolution of an F-18 agent. The 511 keV photon pair is created where the positron annihilates, not where the nucleus decayed, so the average annihilation displacement adds a blur term to the system point-spread function. Conceptually, intrinsic resolution combines in quadrature:

where $r_{\text{detector}}$ is the detector/crystal contribution, $r_{\text{range}}$ is the positron-range blur (larger for Ga-68), and $r_{\text{noncollinearity}}$ accounts for the slight departure from exactly 180° between the two photons. In modern clinical PET, detector size and reconstruction usually dominate the delivered resolution, so the Ga-68 range penalty is modest in practice — but it is real, larger in low-density tissue, and one reason reconstruction settings deserve scrutiny in a quantitative SSTR program.⁸

The SUV quantification chain

SUV is only as trustworthy as the calibration chain behind it. For a body-weight-normalized SUV, the working definition is:

where $C_{\text{tissue}}$ is the decay-corrected activity concentration in the region of interest (for example, kBq/mL), $A_{\text{injected}}$ is the net injected activity decay-corrected to the scan reference time, and $W$ is patient body weight. Every quantity is a potential error source: $C_{\text{tissue}}$ depends on the scanner's absolute calibration to a traceable source and on correct attenuation and scatter correction; $A_{\text{injected}}$ depends on the dose calibrator being cross-calibrated to the scanner, accurate residual-activity measurement, and the correct injection time; and $W$ must be the patient's weight at the time of the scan. A break anywhere in that chain biases SUV directly and silently. We develop this in depth in our guides to PET SUV quantification and dose calibrator quality control.

EARL/EANM harmonization for SUV

Because SUV is compared across visits, scanners, and sites, harmonization matters. The EANM Research Ltd. (EARL) accreditation program defines phantom-based specifications — recovery coefficients from a NEMA image-quality phantom and cross-calibration checks with a uniform phantom — so that quantitative PET is comparable regardless of the system used. EARL recovery-coefficient standards were originally derived for F-18 FDG; a multicentre study showed that Ga-68 PET/CT quantification sits on the lower limits of the current EARL F-18 recovery-coefficient standards, and recommended correcting for local Ga-68/F-18 cross-calibration mismatch while keeping the EARL reconstruction protocol rather than maintaining separate protocols.⁹ The practical message: do not assume an F-18-tuned SUV pipeline is automatically valid for Ga-68 — verify it. See our dedicated primer on EARL PET SUV harmonization.

The Krenning score

Visual interpretation of SSTR imaging is standardized with the Krenning score, a 0-to-4 grading of tumor uptake against normal reference tissue: 0, no uptake; 1, very low uptake below normal liver; 2, uptake less than or equal to the liver; 3, uptake greater than the liver; and 4, uptake greater than the normal spleen or kidney.¹⁷ Originally defined for In-111 pentetreotide, the scale was carried over to Ga-68 SSTR PET, where a score of 3 or 4 (uptake above liver background) is commonly used to indicate sufficient receptor expression for peptide-receptor radionuclide therapy (PRRT). Because Ga-68 DOTATATE has higher intrinsic contrast and resolution than In-111 pentetreotide, a given lesion often scores higher on PET than on the older scintigraphy — a shift that directly affects therapy eligibility, as shown in a head-to-head comparison of the two modalities.⁷

Clinical Impact

The physics and QC choices above translate directly into clinical reliability. When the calibration chain is intact and the scanner performs to specification, SUVs and Krenning scores can support detection, staging, and theranostic selection. When it is not, errors masquerade as biology.

The evidence base for Ga-68 SSTR PET is strong. A systematic review and meta-analysis reported pooled sensitivity and specificity around 90% or higher for detecting NETs, and comparisons against In-111 pentetreotide and conventional imaging consistently favor the PET agent.³⁴ In a prospective study, Ga-68 DOTATATE PET/CT was equivalent or superior to In-111 pentetreotide in every patient and changed management in about 36% of participants, and it correctly identified therapy candidates that pentetreotide had misclassified.² Prospective work with the related agent Ga-68 DOTATOC found a major change in management in roughly 47% of NET patients.⁶ The scan also underpins selection for Lu-177 DOTATATE therapy, tying diagnostic quality directly to a therapeutic decision.¹¹⁰

FDG PET plays a complementary, not competing, role. Well-differentiated, low-grade NETs are typically SSTR-avid and FDG-cold, whereas higher-grade or dedifferentiated tumors tend to lose somatostatin-receptor expression and gain glucose avidity — the so-called flip-flop phenomenon. Discordant SSTR-negative, FDG-positive disease carries a worse prognosis and may be better treated with chemotherapy than PRRT, which is why some centers use both tracers to phenotype aggressive or heterogeneous disease.¹ The three tracers occupy distinct niches:

This comparison summarizes the roles established in the SSTR PET guideline and the comparative literature.¹²³⁷

Physiologic biodistribution is central to interpretation and is a frequent source of pitfalls. Normal Ga-68 DOTATATE uptake is expected — and often intense — in the spleen (usually the highest normal uptake), adrenal glands, pituitary, kidneys, liver, and the pancreatic uncinate process, with excretion producing bladder and bowel activity. The uncinate-process pitfall is classic: physiologic uptake in the pancreatic head can mimic a primary tumor. Accessory spleens and splenosis, reactive lymph nodes, inflammation, osteoblastic bone changes, and healing fractures can all show SSTR uptake and be mistaken for disease. The interpreting physician and physicist should know the expected biodistribution before attributing a focus to malignancy.¹

Practical Optimization Tips

Production and on-site radiochemistry

Ga-68 for DOTATATE is most often produced by eluting a Ge-68/Ga-68 generator on site. The parent germanium-68 has a long half-life (about 271 days), so a single generator supplies gallium-68 for months; the eluate is combined with the NETSPOT cold kit and reacted to form the labeled product.⁵ Some programs instead use cyclotron-produced Ga-68, which can yield larger batches for higher throughput. Practical points:

• Elution yield declines over the generator's life; track yield and breakthrough trends over time.
• The short half-life caps how many patient doses one elution supports — schedule accordingly.
• On-site production makes the facility a manufacturer of the final dose, so the quality system, not just the scanner, is in scope. Our companion guide to Ge-68/Ga-68 generator quality control covers elution efficiency and breakthrough testing.

Radiopharmaceutical quality control

Each prepared batch should be tested per the kit prescribing information and applicable pharmacopeial standards (for example, the USP gallium Ga 68 dotatate monograph and EANM radiopharmacy guidance) before release.⁵¹¹ Core tests typically include:

• Radiochemical purity — usually by thin-layer chromatography (TLC/iTLC) or HPLC, confirming the Ga-68 is bound to DOTATATE rather than free Ga-68 or colloid; see our primer on radiochemical purity and TLC quality control.
• Radionuclidic purity / Ge-68 breakthrough — confirming that long-lived Ge-68 in the final product is within the specified limit, controlled by the generator and kit specifications.
• pH, appearance, and radiochemical identity, plus any kit-specified checks. Always verify the exact acceptance limits and methods against the prescribing information for the kit and generator in use.

Acquisition protocol

• Administered activity. The FDA-approved NETSPOT labeling recommends 2 MBq/kg (0.054 mCi/kg) up to a maximum of 200 MBq (5.4 mCi) as an intravenous bolus, verified within ±10% by a dose calibrator before injection.⁵
• Uptake time. NETSPOT labeling directs that PET imaging begin 40 to 90 minutes after injection; the SSTR PET guideline describes a comparable window.¹⁵ Keep the interval consistent to make SUVs comparable across visits, a point we develop in PET imaging uptake time.
• Somatostatin-analogue timing. Long-acting "cold" somatostatin analogues can competitively block receptor binding and reduce tumor uptake, so SSTR PET is generally scheduled before the next long-acting depot dose (commonly imaging just before the scheduled injection), per the procedure guideline.¹

Scanner performance and SUV calibration

A quantitative SSTR program should hold scanner performance and SUV calibration to documented standards:

• Cross-calibrate the PET scanner and dose calibrator on a defined schedule using a traceable source, and verify the SUV calibration with a uniform phantom, correcting for Ga-68/F-18 differences where an EARL F-18 pipeline is in place.⁹
• Standardize the protocol — injected activity, uptake time, acquisition, and reconstruction — so SUVs and Krenning scores are reproducible across visits and scanners.
• Confirm acquisition-mode performance through periodic NEMA NU-2 performance testing, which characterizes sensitivity, spatial resolution, noise-equivalent count rate, scatter fraction, and image quality.¹² Our guide to PET/CT performance testing with NEMA NU-2 walks through these metrics; time-of-flight and modern iterative reconstruction improve effective signal-to-noise for the relatively count-limited Ga-68 acquisition.

Common pitfalls to avoid

• Sloppy injection-time recording. With a 68-minute half-life, a few minutes of timing error is a few percent of SUV error.
• Ignoring residual activity. Uncounted syringe residual inflates the assumed injected activity and biases SUV downward.
• Assuming F-18 SUV harmonization transfers to Ga-68. Ga-68 sits at the lower limits of EARL F-18 recovery standards; verify, do not assume.⁹
• Misreading physiologic uptake. The pancreatic uncinate process, spleen, and accessory splenic tissue are classic false positives.¹
• Scanning through a somatostatin-analogue block. Poor timing relative to long-acting therapy can suppress tumor uptake and lower Krenning scores.¹

Regulatory Considerations

A Ga-68 DOTATATE program sits at the intersection of radioactive-material licensing, radiopharmaceutical quality standards, and imaging performance standards. Each must be addressed and documented.

• Medical use of byproduct material. Ga-68 is byproduct material; possession and medical use fall under 10 CFR Part 35 (or the equivalent Agreement State program), with dose limits under 10 CFR Part 20. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. Generator possession, elution, and on-site preparation should be reflected in the license and radiation safety program.
• Radiopharmaceutical quality. On-site preparation should follow the FDA-approved NETSPOT prescribing information, the applicable USP gallium Ga 68 dotatate monograph, and EANM radiopharmacy guidance, with documented release testing.⁵¹¹
• Imaging performance and accreditation. Quantitative SSTR imaging benefits from NEMA NU-2 performance characterization and from accreditation-program requirements for calibration, phantom QC, and physicist oversight.¹² DRPS provides this through accreditation support and medical physicist consulting.
• Acquisition and interpretation standards. The joint SNMMI/EANM/IAEA SSTR PET/CT procedure guideline defines indications, acquisition, biodistribution, and interpretation, and the Krenning score standardizes reporting.¹⁷ Because Ga-68 DOTATATE is also a patient-selection tool for Lu-177 DOTATATE, radiation dosimetry and therapy-side controls come into scope as well, as discussed in our Lu-177 theranostics dosimetry guide.

Radiation burden is a point in favor of the PET agent: the effective dose from a Ga-68 DOTATATE study is comparable to other Ga-68 PET agents and lower than an In-111 pentetreotide scan, consistent with published dosimetry compendia and with prospective comparisons.²⁸

Frequently Asked Questions (FAQs)

What is Ga-68 DOTATATE PET/CT used for?

Ga-68 DOTATATE PET/CT images neuroendocrine tumors by targeting somatostatin receptor subtype 2, which most well-differentiated NETs overexpress. It is used to detect and localize primary and metastatic disease, to stage and restage, and to select and monitor patients for somatostatin-receptor-targeted therapy such as Lu-177 DOTATATE. It has largely replaced In-111 pentetreotide (OctreoScan) where PET is available.¹²

How is Ga-68 DOTATATE different from Ga-68 PSMA PET?

Both use the same Ga-68 radionuclide and the same 68-minute half-life and positron physics, but they target different receptors for different cancers. Ga-68 DOTATATE binds somatostatin receptors on neuroendocrine tumors, while Ga-68 PSMA-11 binds prostate-specific membrane antigen on prostate cancer. They use different reporting frameworks — the Krenning score for DOTATATE and PSMA-RADS/E-PSMA for PSMA — and pair with different Lu-177 therapies.¹⁸

What is the Krenning score?

The Krenning score is a 0-to-4 visual grading of tumor somatostatin-receptor uptake relative to normal tissue: 0 is no uptake, 1 is very low uptake, 2 is uptake less than or equal to the liver, 3 is uptake greater than the liver, and 4 is uptake greater than the normal spleen or kidney. It was developed for In-111 pentetreotide and adapted to Ga-68 SSTR PET, where a score of 3 or 4 (uptake above the liver) is commonly used to support eligibility for peptide-receptor radionuclide therapy.¹⁷

Why is Ga-68 DOTATATE better than In-111 pentetreotide (OctreoScan)?

Ga-68 DOTATATE PET/CT offers higher spatial resolution, quantitative SUV, higher SSTR2 affinity, a same-day exam, and lower radiation dose than In-111 pentetreotide SPECT. Meta-analyses and head-to-head studies report higher lesion detection and frequent changes in management, and Ga-68 DOTATATE can correctly identify therapy candidates that OctreoScan misclassifies.²³⁷

How much Ga-68 DOTATATE is injected and when is the patient imaged?

The FDA-approved NETSPOT labeling recommends 2 MBq/kg (0.054 mCi/kg) of body weight up to a maximum of 200 MBq (5.4 mCi), given as an intravenous bolus, with PET imaging beginning 40 to 90 minutes after injection. A consistent uptake interval matters because a reproducible time supports comparable SUVs across visits.⁵

How does Ga-68 DOTATATE relate to Lu-177 DOTATATE therapy?

They are a theranostic pair built on the same somatostatin-analogue targeting vector. Ga-68 DOTATATE PET shows whether a tumor expresses enough somatostatin receptor to be treated, and Lu-177 DOTATATE delivers a beta-emitting therapeutic dose to those same receptors. The phase 3 NETTER-1 trial established Lu-177 DOTATATE for progressive midgut NETs, and SSTR PET is the imaging gate for selecting and following those patients.¹¹⁰

Key Takeaways

• The radionuclide drives the workflow. Ga-68's ~68-minute half-life, ~89% positron branching, and ~1.9 MeV maximum positron energy set the logistics, decay correction, and resolution limits of an SSTR PET program.⁸
• The vector drives the biology and the theranostic pair. DOTATATE binds SSTR2, and swapping Ga-68 for Lu-177 on the same peptide turns the diagnostic scan into targeted therapy.¹¹⁰
• SUV is a chain, not a number — and Ga-68 needs its own harmonization. Scanner calibration, dose-calibrator cross-calibration, injection time, weight, and decay correction must all be right, and F-18 EARL standards do not transfer to Ga-68 unchecked.⁹
• The Krenning score standardizes therapy selection. A 0-to-4 grade against liver and spleen turns receptor imaging into a reproducible eligibility signal for PRRT.¹⁷
• DOTATATE outperforms OctreoScan and complements FDG. SSTR PET detects more disease at lower dose than In-111 pentetreotide, while FDG flags the high-grade, receptor-negative disease PRRT may not reach.¹²³

Conclusion

Ga-68 DOTATATE PET/CT has redefined neuroendocrine tumor imaging, but its clinical power rests on disciplined physics and quality control. The short half-life makes decay correction and injection timing critical; the energetic positrons impose a small but real resolution penalty; on-site generator production turns the facility into a manufacturer with radiochemical, radionuclidic, and breakthrough obligations; and the SUV is only as good as the weakest link in its calibration chain — a chain that must be re-verified for Ga-68 rather than inherited from an F-18 pipeline. Layered on top, the Krenning score and the joint SSTR PET procedure guideline keep interpretation reproducible.

Treated as one integrated quality system — agent, scanner, and interpretation together — Ga-68 DOTATATE PET/CT produces studies clinicians can trust for detection, staging, and, above all, selecting the patients who will benefit from Lu-177 DOTATATE. That theranostic link is what makes SSTR PET quality a therapeutic issue, not just a diagnostic one.

How DRPS Can Help

Diagnostic Radiation Physics Services helps PET/CT and nuclear medicine programs build defensible quantitative imaging. For Ga-68 DOTATATE services, this can include PET/CT and nuclear medicine physics support, scanner-to-dose-calibrator cross-calibration and SUV verification with attention to Ga-68/F-18 harmonization, NEMA NU-2 performance testing, radiopharmaceutical QC program review, accreditation support, and medical physicist consulting aligned with NRC and Agreement State requirements.

DRPS supports facilities across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware. A strong SSTR PET program is not just about acquiring images — it is about making the trustworthy result the routine result for the clinical and theranostic team.

Related Resources

• Ga-68 PSMA PET/CT: physics, SUV, and QC
• Ge-68/Ga-68 generator quality control
• Common PET & RPT isotopes
• EARL PET SUV harmonization
• PET SUV quantification
• Lu-177 theranostics dosimetry
• PET/CT and nuclear medicine physics
• Accreditation support

References

1. Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. European Journal of Nuclear Medicine and Molecular Imaging. 2017;44(9):1588-1601. doi:10.1007/s00259-017-3728-y. doi.org
2. Deppen SA, Liu E, Blume JD, et al. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. Journal of Nuclear Medicine. 2016;57(5):708-714. doi:10.2967/jnumed.115.163865. doi.org
3. Deppen SA, Blume JD, Bobbey AJ, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. Journal of Nuclear Medicine. 2016;57(6):872-878. doi:10.2967/jnumed.115.165803. doi.org
4. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of gallium-68 DOTATOC and gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiologica. 2014;55(4):389-398. doi:10.1177/0284185113496679. doi.org
5. U.S. Food and Drug Administration. NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection) prescribing information. accessdata.fda.gov
6. Ghobrial SN, Menda Y, Zamba GK, et al. Prospective analysis of the impact of 68Ga-DOTATOC positron emission tomography-computerized axial tomography on management of pancreatic and small bowel neuroendocrine tumors. Pancreas. 2020;49(8):1033-1036. doi:10.1097/MPA.0000000000001625. doi.org
7. Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. Journal of Nuclear Medicine. 2019;60(9):1266-1269. doi:10.2967/jnumed.118.223016. doi.org
8. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Annals of the ICRP. 2015;44(2 Suppl). icrp.org
9. Huizing DMV, Koopman D, van Dalen JA, et al. Multicentre quantitative 68Ga PET/CT performance harmonisation. EJNMMI Physics. 2019;6(1):19. doi:10.1186/s40658-019-0253-z. doi.org
10. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1). New England Journal of Medicine. 2017;376(2):125-135. doi:10.1056/NEJMoa1607427. doi.org
11. The United States Pharmacopeial Convention. Gallium Ga 68 dotatate injection monograph; radiopharmaceutical preparation standards. usp.org
12. National Electrical Manufacturers Association. NEMA NU 2: Performance Measurements of Positron Emission Tomographs (PET). Rosslyn, VA: NEMA. nema.org